Filing Flows › Evolent Health (EVH) › Q3 2026 › vs Q2 2026
Evolent Health (EVH) Q3 2026 vs Q2 2026 (quarter over quarter)
Evolent Health's revenue rose $72.8M (+11%) from $653M in Q2 2026 to $725M in Q3 2026.
Evolent Health, Q3 2026: revenue $725M (+51% year over year), operating margin -0.9%, net loss $23.6M, operating cash flow $26.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $725M | $653M | $72.8M | +11% |
| Net loss | $23.6M | $28.4M | −$4.8M | -17% |
| Costs & expenses | $749M | $681M | $68.0M | +10% |
| Operating costs | $732M | $662M | $69.5M | +10% |
| Interest & other, net | $16.3M | $16.1M | $172K | +1% |
| Income tax | $1.1M | $2.7M | −$1.6M | -59% |
| Cost of revenue | $637M | $572M | $65.3M | +11% |
| SG&A | $73.1M | $68.8M | $4.3M | +6% |
| Other operating costs | $21.5M | $21.6M | −$73K | -0.3% |
| Operating cash sources | $49.9M | $19.1M | $30.9M | +162% |
| Depreciation & amortization | $21.5M | $21.6M | −$73K | -0.3% |
| Share-based compensation | $14.8M | $15.2M | −$397K | -3% |
| Working capital & other | $13.6M | −$17.7M | $31.4M | — |
| Net loss absorbed | $23.6M | $28.4M | −$4.8M | -17% |
| Operating cash flow | $26.4M | −$9.3M | $35.7M | — |
Questions
How much did Evolent Health's revenue grow quarter over quarter in Q3 2026?
Evolent Health's revenue rose $72.8M (+11%) from $653M in Q2 2026 to $725M in Q3 2026.